arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Kalaris Therapeutics, Inc.

KLRS

$4.06 ▼ -0.06 (-1.34%) at close

8 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Kalaris Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $62.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -58.6% ↘

FCF / Share $-2.53 ↗

Trailing P/E —

Price / Book 1.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-43.44M

↑ +37.2% —

FCF / Share Free cash flow per share

$-2.53

↑ +83.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	94.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-2729.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	16.8% Good Good Year-over-year change in earnings per share Optimal: > 10%	19.7% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	37.2% Excellent ↑ Excellent Improving Year-over-year change in net income	63.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-12.9% Weak ↑ Weak Improving Year-over-year change in net income	1.9% Caution ↑ Caution Improving Year-over-year change in net income	-146.4% Weak Weak Year-over-year change in net income	-192.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	83.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1193.7% Weak ↓ Weak Declining Year-over-year change in free cash flow	35.5% Excellent Excellent Year-over-year change in free cash flow	-9.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.30x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-58.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	53.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-137.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-76.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-75.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	41.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-37.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-839.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-104.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-61.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-19.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-55.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-467%)	71.6% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+377%)	-130.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-971%)	-75.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-601%)	-76.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-609%)	-19.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-232%)	46.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+209%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	-31.98x Weak Weak Operating income divided by interest expense Optimal: > 5x	-19.15x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	-213.61x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-98.05M	$-1.64M	$-90.12M	$-106.09M	$-201.66M	$-122.66M	$-61.08M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-2.85	$-51.77	$-1.83	$-2.20	$-2.74	—	—	—
Free Cash Flow per Share (USD)	$-2.53	$-15.47	$-1.20	$-1.85	$-1.69	—	—	—
Book Value per Share (USD)	$3.44	$-71.23	$1.28	$2.41	$3.54	$5.70	$-24.53	—
Tangible Book Value per Share (USD)	$3.44	$-71.23	$1.28	$2.41	$3.54	$5.70	$-24.53	—
Basic Weighted Avg Shares (shares)	15.27M	1.34M	104.06M	76.65M	62.78M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$109.09M	$-22.10M	$159.27M	$218.71M	$215.50M	$349.02M	$118.21M	—
Total Equity (USD)	$78.81M	$-96.62M	$145.78M	$224.52M	$225.27M	$353.06M	$-51.50M	$-30.62M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	$165.00K	—
Depreciation Expense (USD)	$13.00K	—	$398.00K	$723.00K	$189.00K	$73.00K	$19.00K	—
Net Income, GAAP (USD)	$-43.44M	$-69.17M	$-190.42M	$-168.71M	$-171.96M	$-69.78M	$-23.84M	—
Operating Cash Flow (USD)	$-38.37M	$-20.67M	$-124.45M	$-142.05M	$-106.32M	$-60.81M	$-20.16M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Kalaris Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KLRS with peers